Drug treatment of COVID-19 infection : Current Opinion in Pulmonary Medicine

Secondary Logo

Journal Logo

INFECTIOUS DISEASES: Edited by Alimuddin Zumla and David SC Hui

Drug treatment of COVID-19 infection

Lui, Gracea; Guaraldi, Giovannib

Author Information
Current Opinion in Pulmonary Medicine 29(3):p 174-183, May 2023. | DOI: 10.1097/MCP.0000000000000953


Purpose of review 

COVID-19 pandemic has caused more than 6.6 million deaths globally. Tremendous efforts have been committed for the development of new and repurposed drugs for the treatment of COVID-19. Although different international and national guidelines share consensus in the management of COVID-19 disease with different levels of severity, new challenges have emerged, steering the need for ongoing research in advancing the clinical management of COVID-19.

Recent findings 

This review focuses on recent data from randomized trials and postmarketing real-world evidence for the treatment of mild to moderate disease in the outpatient setting and patients hospitalized for COVID-19 with varying level of severity. Relevant data for treatment of the latest omicron sub-variants in people who received vaccination are presented. Challenges in special populations, including immunocompromised hosts, patients with renal failure and pregnant women, are also discussed.


Treatment of COVID-19 should be personalized according to host characteristics, degree of severity and available treatment options.

Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.

You can read the full text of this article if you:

Access through Ovid